Michelino De Laurentiis

Author

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"ORCID

Also Known As

C. S. P. Ang, Carlo Tondini, De Laurentiis, Michelino, Italy, John McCaffrey, M DELAURENTIIS, M De Laurentiis, M Inoue, M de Laurentiis, M. DE LAURENTIIS

667

Publications

23.7K

Citations

H-Index

146

Concepts

All Affiliations

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"University of Naples Federico II Seoul National University Hospital Istituti di Ricovero e Cura a Carattere Scientifico Fondazione IRCCS Istituto Nazionale dei Tumori

About

Michelino De Laurentiis is an author at Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" specializing in medicine, oncology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	41	87	8.1K
2	Health Sciences	15	21	2.5K
3	Engineering	5	5	203
4	Nursing	3	3	331
5	Public Health	3	3	126

Michelino De Laurentiis

178

Publications

17.1K

Citations

H-Index

Page 1

	Year	Citations
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3 Dennis J. Slamon, Patrick Neven, Stephen Chia, Journal of Clinical Oncology Advanced Breast CancerFulvestrant V PlaceboBreast OncologyHealth SciencesMedicine	2018	1.1K
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial Debu Tripathy, Seock‐Ah Im, Marco Colleoni, The Lancet Oncology Advanced Breast CancerBreast OncologyOncologyEndocrine OncologyMedicine	2018	973
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer Dennis J. Slamon, Patrick Neven, Stephen Chia, New England Journal of Medicine	2019	797
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer David Miles, Joseph Gligorov, Fabrice André, Annals of Oncology	2021	689
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study Sylvia Adams, Sherene Loi, Deborah Toppmeyer, Annals of Oncology	2018	608
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial Cristina Saura, Mafalda Oliveira, Yin‐Hsun Feng, Journal of Clinical Oncology	2020	588
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial José Baselga, Seock‐Ah Im, Hiroji Iwata, The Lancet Oncology Advanced Breast CancerBreast OncologyOncologyClinical TrialsGynecology	2017	532
Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Giuseppe Di Lorenzo, Giampaolo Tortora, Francesco Paolo D’Armiento, PubMed	2002	475
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial Sung‐Bae Kim, Rebecca Dent, Seock‐Ah Im, The Lancet Oncology First-line TherapyBreast OncologyMedicinePharmacologyClinical Trials	2017	463
c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. Chiara Carlomagno, Francesco Perrone, Ciro Gallo, Journal of Clinical Oncology	1996	409

Page 1